Evidence map›Paper›PMID 31017258›Full record

ArticleInternational journal of molecular medicine2019

[Erratum] MicroRNA-101 inhibits autophagy to alleviate liver ischemia/reperfusion injury via regulating the mTOR signaling pathway.

Hu Song, Chenyang Du, Xingxing Wang, Jianjun Zhang, Zhongyang Shen

Abstract readPublished Erratum
In one paragraph

Article in International journal of molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. [Autophagy in the liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020
    Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Hu SongFirst Central Clinical College, Tianjin Medical University, Tianjin 300070, P.R. China.
Chenyang DuFirst Central Clinical College, Tianjin Medical University, Tianjin 300070, P.R. China.
Xingxing WangFirst Central Clinical College, Tianjin Medical University, Tianjin 300070, P.R. China.
Jianjun ZhangFirst Central Clinical College, Tianjin Medical University, Tianjin 300070, P.R. China.
Zhongyang ShenFirst Central Clinical College, Tianjin Medical University, Tianjin 300070, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Owing to oversights during the production process, a pair of errors were introduced into the above article. First, in the Materials and methods section, Animals and cell lines subsection, on p. 1332, line 12, the sentence starting here should have read as: 'The non‑tumorigenic mouse hepatocyte alpha mouse liver 12 (AML12) cell line was purchased from the Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China)' (i.e., the abbreviation AML12 was expanded incorrectly). Secondly, the bottom row of data was accidentally omitted from Table I (pertaining to the Suzuki score for liver ischemia/reperfusion injury assessed to be severe).The fifth data row in the Table should have read, from left to right, as follows: Numerical assessment, '4'; Congestion, 'Severe (>60%)'; Vacuolization, 'Severe (>60%)'; and Necrosis, 'Severe (>60%)'.We regret that these errors were introduced into the published version of this paper, and apologize to the authors and the readership for the inconvenience caused. [the original article was published in International Journal of Molecular Medicine 43: 1331‑1342, 2019; DOI: 10.3892/ijmm.2019.4077].

Identifiers

PMID31017258
PMCPMC6488181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.